HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5832-5844

  Feng, Jin ^a   Yu, Junbo ^a   Pan, Xiaolin ^b   Li, Zengliang ^a   Chen, Zheng ^a   Zhang, Wenjie ^a   Wang, Bin ^a   Yang, Li ^a   Xu, Hao ^a   Zhang, Guoxin ^a   Xu, Zekuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Anticancer therapy; HERG1; miR 96; Pancreatic cancer

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 96; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ERG1 POTASSIUM CHANNEL; MIRN96 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HERG1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; GENE EXPRESSION; GENETICS; METABOLISM; PANCREAS TUMOR; PROGNOSIS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

AGED; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84906342501     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2200     Document Type: Article

References (52)

1. Raimondi S, Maisonneuve P and Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009; 6(12):699-708.
2. Shaib YH, Davila JA and El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006; 24(1):87-94.
3. Li D, Xie K, Wolff R and Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363(9414):1049-57.
4. Guo X and Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005; 31(1):13-22.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225-49.
6. Pliarchopoulou K and Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev. 2009; 35(5):431-6.
7. Sato N and Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006; 13(4):286-95.
8. Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10(8):789-99.
9. Feldmann G, Beaty R, Hruban RH and Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007; 14(3):224-32.
10. Wonderlin WF and Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol. 1996; 154(2): 91-107.
11. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, Brackenbury WJ, Theodorou D, Koyutürk M, Kaya H, Battaloglu E, De Bella MT and et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 2005; 11(15):5381-9.
12. Li M, Wang Q, Lin W and Wang B. Regulation of ovarian cancer cell adhesion and invasion by chloride channels. Int J Gynecol Cancer. 2009; 19(4):526-30.
13. Vanden Abeele F, Roudbaraki M, Shuba Y, Skryma R and Prevarskaya N. Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1. J Biol Chem. 2003; 278(17):15381-9.
14. Kunzelmann K. Ion channels and cancer. J Membr Biol. 2005; 205(3):159-73.
15. Trudeau MC, Warmke JW, Ganetzky B and Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995; 269(5220):92-5.
16. Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M and Arcangeli A. HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer. 2000; 83(12):1722-9.
17. Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J and Fan DM. Expression and significance of HERG protein in gastric cancer. Cancer Biology & Therapy. 2008; 7(1):45-50.
18. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, Moretti R, Wanke E, Olivotto M, Mugnai G and Arcangeli A. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 2004; 64(2):606-11.
19. + channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007; 110(4):1238-50.
20. Afrasiabi E, Hietamäki M, Viitanen T, Sukumaran P, Bergelin N and Törnquist K. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cellular Signalling. 2010; 22(1):57-64.
21. Wang H, Zhang Y, Cao L, Han H, Wang J, Yang B, Nattel S and Wang Z. HERG K+ channel, a Regulator of Tumor Cell Apoptosis and Proliferation. Cancer Res. 2002; 62(17):4843-8.
22. Zhou B, Irwanto A, Guo YM, Bei JX, Wu Q, Chen G, Zhang TP, Lei JJ, Feng QS, Chen LZ, Liu J and Zhao YP. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2012; 13(10):871-9.
23. Bushati N and Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175-205.
24. Carthew RW and Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55.
25. Garzon R, Calin GA and Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009; 60:167-79.
26. Slack FJ and Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med. 2008; 359:2720-2.
27. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N and Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009; 113:396-402.
28. Taganov KD, Boldin MP, Chang KJ and Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006; 103(33): 12481-6.
29. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH and Cai JP. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 2012; 4(2):339-45.
30. Wang Y, Luo H, Li Y, Chen T, Wu S and Yang L. hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. Mol Med Report. 2012; 5(1):260-5.
31. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X and Song L. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2010; 5(12):e15797.
32. Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST and Sif S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 2007; 26(15):3558-69.
33. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26(30):4442-52.
34. Lang F, Föller M, Lang KS, Lang PA, Ritter M, Gulbins E, Vereninov A and Huber SM. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol. 2005; 205(3):147-57.
35. Lang F, Ritter M, Gamper N, Huber S, Fillon S, Tanneur V, Lepple-Wienhues A, Szabo I and Gulbins E. Cell volume in the regulation of cell proliferation and apoptotic cell death. Cell Physiol Biochem. 2000; 10(5-6):417-28.
36. Camacho J. Ether a go-go potassium channels and cancer. Cancer Lett. 2006; 233(1):1-9.
37. Arcangeli A, Bianchi L, Becchetti A, Faravelli L, Coronnello M, Mini E, Olivotto M and Wanke E. A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J Physiol. 1995; 489(pt 2):455-71.
38. Pardo LA, Brüggemann A, Camacho J and Stühmer W. Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol. 1998; 143(3):767-75.
39. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6-7.
40. Hwang HW and Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006; 94(6):776-80.
41. Gregory RI and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005; 65(9):3509-12.
42. Bhatti I, Lee A, James V, Hall RI, Lund JN, Tufarelli C, Lobo DN and Larvin M. Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2011; 15(1):199-208.
43. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R and Li Y. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 2011; 30(1):57-67.
44. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A and et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 2007; 104(41):16170-5.
45. Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P and Amin HM. MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression. Am J Pathol. 2012; 180(5):1772-80.
46. Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST and Sif S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 2007; 26(15):3558-69.
47. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and García-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 206; 5:29.
48. Ma L, Huang Y, Zhu W, Zhou S, Zhou J, Zeng F, Liu X, Zhang Y and Yu J. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 2011; 6(10):e26502.
49. Wang Y, Luo H, Li Y, Chen T, Wu S and Yang L. hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. Mol Med Report. 2012; 5(1):260-5.
50. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010; 70(1):367-77.
51. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J and Chen J. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010; 70(14):6015-25.
52. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y and Soong R. MicroRNA-130b regulates the tumor suppressor RUNX3 in gastric cancer. Eur J Cancer. 2010; 46(8):1456-63.